cyclic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Albumin is a family of globular proteins, the most common of which are the serum albumins. All of the proteins of the albumin family are water-soluble, moderately soluble in concentrated salt solutions, and experience heat denaturation. Albumins are commonly found in blood plasma and differ from other blood proteins in that they are not glycosylated. Substances containing albumins are called albuminoids. A number of blood transport proteins are evolutionarily related in the albumin family, including serum albumin, alpha-fetoprotein, vitamin D-binding protein and afamin. This family is only found in vertebrates. Albumins in a less strict sense can mean other proteins that coagulate under certain conditions. See § Other albumin types for lactalbumin, ovalbumin and plant "2S albumin".
== Further reading == Banting, F.G. & Best, C.H. (1922), "The Internal Secretions of the Pancreas", The Journal of Laboratory and Clinical Medicine, Vol.7, No.5, (February 1922), pp. 251–266. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it". Henry B. M. Best (2003). Margaret and Charley: The Personal Story of Dr. Charles Best, the Co-Discoverer of Insulin. Dundurn Press Ltd. ISBN 1-55002-399-3. John Waller (2002) Fabulous Science: fact and fiction in the history of scientific discovery, Oxford. See Chapter 11: "Painting yourself into a corner; Charles Best and the discovery of insulin", page 223.
Huntington's disease has autosomal dominant inheritance, meaning that an affected individual typically inherits one copy of the gene with an expanded trinucleotide repeat (the mutant allele) from an affected parent. Since the penetrance of the mutation is very high, those who have a mutated copy of the gene will have the disease. In this type of inheritance pattern, each offspring of an affected individual has a 50% risk of inheriting the mutant allele and developing the disease (see figure). This probability is sex-independent since the huntingtin gene is not located on the X or Y chromosomes. Trinucleotide CAG repeats numbering over 28 are unstable during replication, and this instability increases with the number of repeats present. This usually leads to new expansions as generations pass (dynamic mutations) instead of reproducing an exact copy of the trinucleotide repeat. This causes the number of repeats to change in successive generations, such that an unaffected parent with an "intermediate" number of repeats (28–35), or "reduced penetrance" (36–40), may pass on a copy of the gene with an increase in the number of repeats that produces fully penetrant HD. The earlier age of onset and greater severity of disease in successive generations due to increases in the number of repeats is known as genetic anticipation. Instability is greater in spermatogenesis than oogenesis; maternally inherited alleles are usually of a similar repeat length, whereas paternally inherited ones have a higher chance of increasing in length.
Some cases of chronic intracranial hypotension due to CSF leak may present as personality changes, altered behaviors and impairment of executive functions, similar to behavioral-variant frontotemporal dementia as the frontal and temporal lobes are affected by downward sagging due to reduced intra-cranial pressures. An untreated CSF leak can result in coma or death as late stage findings as the brainstem herniates through the skull base or foramen magnum.
Sources: en.wikipedia.org
Ibrahim Ahmad Maqary - Professor of Arabic and linguistics, Current Co-imam of the Abuja National Mosque. Iya Abubakar – Professor of Mathematics at Ahmadu Bello University at the age of 28, first Northern-Nigerian to earn a PhD in any field, former vice-chancellor of Ahmadu Bello University R. A. B. Dikko - first Medical Doctor from Northern Nigeria. Mahmud Modibbo Tukur (1944–1988) -Nigerian historian, scholar and the 4th National President of the Academic Staff Union of universities (ASUU) Muhammad Ali Pate – CEO GAVI; Global Director for Health, Nutrition and Population at the World Bank, professor at Harvard Chan School; former Minister of State for Health, Current Minister Of Health. Mustafa Shehu - first person from Sub-Sahara Africa to be elected president of the World Federation of Engineering Organizations. Umar Garba - professor of electrical and telecommunications engineering, former executive vice-chairman and chief executive Officer of Nigerian Communications Commission Abdul Ganiyu Ambali - veterinary doctor, former vice- chancellor of University of Ilorin. Ibrahim Abubakar - professor of infectious disease epidemiology at University College London, vice provost (health). Fatima Batul Mukhtar - professor of botany, vice- chancellor Azman University. Bello Shehu - neurosurgeon, former chief medical director of the Usman Danfodiyo University Teaching Hospital, Sokoto, National Hospital, Abuja and Medical Director, Federal Medical Centre, Birnin-Kebbi, vice chancellor of The Federal University Birnin-Kebbi.
==== Miniature Mass Spectrometers ==== Conventional mass spectrometers are often large as well as prohibitively expensive and complex in their operation which has led to the increased attractiveness of miniature mass spectrometers (MMS) for a variety of applications. MMS are optimized towards affordability and simple operation, often forgoing the need for experienced technicians, having a low cost of manufacture, and being small enough in size to allow for the transfer of data collection from the laboratory into the field. These advantages often come at the cost of reduced performance where MMS resolution, as well as the limits of detection and quantitation, are often barely adequate to perform specialized tasks. The integration of DMF with MMS has the potential for significant improvement of MMS systems by increasing throughput, resolution, and automation, while decreasing solvent cost, enabling lab grade analysis at a much reduced cost. In one example the use of a custom DMF system for urine drug testing enabled the creation of an instrument weighing only 25 kg with performance comparable to standard laboratory analysis.
The Australian Pharmaceutical Formulary (APF) is the national formulary used by pharmacists in Australia, compiled by the Pharmaceutical Society of Australia. New editions of the APF are released every few years, with the latest edition being the 25th.
=== Poland === The current Polish Armed Forces combat ration (Polish: Zestaw Żywnościowy Indywidualnej Racji Suchej) is packed in a green plastic-foil bag containing: 2 small cans of meat or meat spread or cheese, 2 packages of hard crackers, a tube of sweetened condensed milk, 2 packets of instant coffee, a packet of instant tea, 3 sugar packets, an individually wrapped Vitamin C fortified boiled sweets, a stick of chewing gum, safety matches, a menu and instruction sheet, a plastic bag, and 2 paper towels. Field ration (24h) "RB1" / "RB2" / "RB3" Meal A (breakfast): - goulash 400 g / beans with sausage and meat in tomato sauce 400 g / pork shoulder with rice and vegetables 400 g - pâté 100 g - jam 25 g - crispbread 50 g - instant tea 30 g - fruit bar - flameless heater - sachet water 45 ml Meal B (lunch): - chicken with rice and vegetables 400 g / spaghetti with meat 400 g / bogracz (Hungarian dish densely packed with beef) 400 g - crackers 45 g - instant tea 30 g - condensed milk tube 100 g - dark chocolate 50 g - flameless heater - sachet water 45 ml Meal C (dinner): - canned meat 100 g - crackers 45 g - honey 25 g - instant tea 30 g - fruit bar Accessories: - sugar 10 g x3 - coffee candy x3 - vitamin C candy x3 - chewing gum x3 - salt, pepper x3 - dried fruits 50 g - instant tea - instant borsch - plastic bag - matches - toilet paper - wet wipe tissue x3 - cutlery Energy value 3496,15kcal / 3693,82 kcal / 3459,6 kcal Weight 1.85 kg (4.1 lb)
Another objection questions whether pleasure is the only thing of value for individuals, citing things like virtue, achievement, friendship, and the satisfaction of desires as distinct sources. An influential counterexample to hedonism, proposed by philosopher Robert Nozick (1938–2002), imagines an experience machine that simulates a life filled with pleasures, which would be ideal from the perspective of hedonism. Pointing out that life in this virtual simulation lacks authenticity, Nozick argues that mere pleasure, by itself, is not the only source of value.
Sources: en.wikipedia.org
=== Books === Predictably Irrational: The Hidden Forces That Shape Our Decisions (2008; second edition in 2012). HarperCollins. ISBN 9780061353239 The Upside of Irrationality (2010). HarperCollins. ISBN 9780062008565 The Honest Truth about Dishonesty: How We Lie to Everyone – Especially Ourselves (2012; second edition in 2013). HarperCollins. ISBN 9780062298553 Behavioral Economics Saved My Dog: Life Advice for the Imperfect Human (2015). Oneworld. ISBN 9781780748177 Irrationally Yours: On Missing Socks, Pick-up Lines, and Other Existential Puzzles (2015). HarperCollins. ISBN 9780062380012 Payoff: The Hidden Logic That Shapes Our Motivations (2016). Simon & Schuster / TED. ISBN 9781501120053 Dollars and Sense: How We Misthink Money and How to Spend Smarter (2017). Co-authored with Jeff Kreisler. HarperCollins. ISBN 9780062651228 Small Change: Money Mishaps and How to Avoid Them (2018). Co-authored with Jeff Kreisler. Pan Macmillan. ISBN 9781509889167 Amazing Decisions: The Illustrated Guide to Improving Business Deals and Family Meals (2019, illustrated by Matt R. Trower), Farrar, Straus and Giroux.ISBN 9781466899544 Misbelief: What Makes Rational People Believe Irrational Things (2023), Bonnier Books UK. ISBN 9781785120787 Professor D Takes Control (2026). Charlesbridge. ISBN 978-1-62354-792-9
To achieve the best balance of blood sugar with either intensive/flexible method, a patient must check his or her glucose level with a meter monitoring of blood glucose several times a day. This allows optimization of the basal insulin and meal coverage as well as correction of high glucose episodes.
=== Visiting positions === He was a visiting professor of biochemistry at the University of California in 1954, and a guest research worker at the Pasteur Institute, Paris, 1957-1958. Later he had many visiting appointments, both in USA and in other countries, including Paraná (Brazil), Kyoto (Japan), Ferrara (Italy), and Rotterdam (The Netherlands).
Retinyl acetate (also called vitamin A acetate or all‑trans‑retinol acetate) is a synthetic, fat‑soluble acetate ester of retinol often used to supply vitamin A in food fortification, dietary supplements, and topical cosmetic products. Because the acetyl group protects the alcohol functionality, the compound is markedly more stable to heat, oxygen and light than free retinol, yet is rapidly hydrolyzed in the human intestine to active retinol after ingestion. Commercially, retinyl acetate is the second most common retinyl ester after retinyl palmitate.
Commonly fluorophores (such as rhodamine or fluorescein) are linked to the ring linked to the sugar (in para) via a flexible arm, presumably extruding from the major groove of the helix. Due to low processivity of the nucleotides linked to bulky adducts such as fluorophores by Taq polymerases, the sequence is typically copied using a nucleotide with an arm and later coupled with a reactive fluorophore (indirect labelling):
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.